Abstract
The long-term view of regenerative medicine therapies predicts an increased need for expansion solutions that are robust and are compatible with limited downstream processing steps. As more cell therapeutics progress through clinical testing, current in vitro culture methods lack efficiency and reproducibility. Moreover, single-use devices and high quality animal origin-free reagents support the future implementation of manufacturing solutions that will be required following clinical success. Here, we describe the implementation of single use bioreactors and high quality media for expansion of cell therapies. We focus on an example of autologous T cells. The presentation will review solutions addressing animal origin-free expansion of cells within the context of different upstream process development steps with good cell yield, high viability and maintenance of identity. Start to finish solutions for manufacturing, including high quality reagents, are key enabling technologies for success in commercializing cell therapies.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call